Proleukin.  Aldesleukin for Injection




Information for Healthcare Professionals

Read Patient Stories


Frequently Asked Questions About Melanoma





What is melanoma?

What causes melanoma?

What are the warning signs?

How is it diagnosed?

What is metastatic melanoma?

How is it treated?

How successful are treatments for patients with melanoma?

Where can I get more information?

1. What is melanoma?

Melanoma is a type of skin cancer that occurs when specialized skin cells called melanocytes become malignant and form a lesion. If the lesion is not removed early, cells can grow downward from the surface of the skin and attack healthy tissue. Medical professionals categorize melanoma into four developmental stages. Please see Melanoma Stages for more information.

2. What causes melanoma?

The exact causes of melanoma are unknown. However, risk factors exist which make a person more prone to the disease. Risk factors for skin cancer, including melanoma, are fair or light skin (sensitivity to the sun), one or more blistering sunburns in childhood, a family history of melanoma, and abnormal moles. Please see Facts About Melanoma for more information.

3. What are the warning signs of melanoma?

Melanoma usually grows from abnormal moles. Melanoma can occur anywhere on the body, including the eyes. The Skin Cancer Foundation outlines how to check for the ABCDs of melanoma (Asymmetry, Border irregularity, Color variation, and Diameter). It is important to consult a physician immediately if a mole or lesion matches any of these conditions. Please see Melanoma Symptoms for more information.

4. How is melanoma diagnosed?

If a mole or a pigmented area on the skin looks abnormal, a physician will biopsy the growth to determine whether it contains cancer cells. If the cells are malignant, or cancer, the physician will then determine the stage of the cancer and what treatment options are currently available.

5. What is metastatic melanoma?

Metastatic melanoma is the most advanced form of melanoma. It occurs when the cancer has spread from the primary lesion on the skin to other parts of the body, where it continues to grow.

6. How is melanoma treated?

The stage of melanoma determines how it is treated. Please see Melanoma Stages for more information. About 95% of cases are treated first with surgery. In stages I and II, the melanoma is usually surgically removed. In stage III, treatment may include drug therapy and/or the removal of surrounding tissue or lymph nodes. In stage IV metastatic melanoma, PROLEUKIN® (aldesleukin) for injection therapy and dacarbazine are the only treatment options approved by the U.S. Food and Drug Administration. Please see Melanoma Treatment for more information.

7. How successful are treatments for patients with melanoma?

Treatment success and survival rates are directly related to the patients' particular stage of melanoma. Please refer to Melanoma Stages for a description of each stage.

8. Where can I get more information?

Your most important information resource is your healthcare team. You can also contact support groups and services through the following organizations. These organizations will be able to direct you to services more specific to your individual needs:

Melanoma Research Foundation (1-800-MRF-1290 [673-1290])
The National Cancer Institute (1-800-4-CANCER)

Please refer to Additional Resources and Links for a list of contact information for these and other organizations.







PROLEUKIN Learning Center


PROLEUKIN® Learning Center
Explore the possibilities. To learn more about PROLEUKIN therapy and see if PROLEUKIN therapy is the appropriate treatment for your metastatic melanoma or metastatic kidney cancer, visit the PROLEUKIN Learning Center.



Treatment Center Finder

Treatment Center Regions

“Everyone with metastatic melanoma or metastatic renal cell carcinoma should find out if they are a candidate for PROLEUKIN therapy.”
Dr. Lee Riley, Medical Director, St. Luke’s Cancer Center, Bethlehem, PA.

Click here to find a PROLEUKIN treatment center nearest to your home.




Stay In Touch


> Submit


PROLEUKIN Product Information Line 1-866-9PROLEUKIN
This site intended for U.S. residents only. ©2008 Novartis Pharmaceuticals Corporation.



PROLEUKIN® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma and metastatic melanoma.

Important Safety Information

Therapy with PROLEUKIN® (aldesleukin) for injection should be restricted to patients with normal cardiac and pulmonary functions as defined by thallium stress testing and formal pulmonary function testing. Extreme caution should be used in patients with a normal thallium stress test and a normal pulmonary function test who have a history of cardiac or pulmonary disease.

PROLEUKIN® should be administered in a hospital setting under the supervision of a qualified physician experienced in the use of anticancer agents. An intensive care facility and specialists skilled in cardiopulmonary or intensive care medicine must be available.

PROLEUKIN® administration has been associated with capillary leak syndrome (CLS) which is characterized by a loss of vascular tone, and extravasation of plasma proteins and fluid into the extravascular space. CLS results in hypotension and reduced organ perfusion which may be severe and can result in death. CLS may be associated with cardiac arrhythmias (supraventricular and ventricular), angina, myocardial infarction, respiratory insufficiency requiring intubation, gastrointestinal bleeding or infarction, renal insufficiency, edema, and mental status changes.

PROLEUKIN® treatment is associated with impaired neutrophil function (reduced chemotaxis) and with an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Consequently, preexisting bacterial infections should be adequately treated prior to initiation of PROLEUKIN® therapy. Patients with indwelling central lines are particularly at risk for infection with gram positive microorganisms. Antibiotic prophylaxis with oxacillin, nafcillin, ciprofloxacin, or vancomycin has been associated with a reduced incidence of staphylococcal infections.

PROLEUKIN® administration should be withheld in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma.

Please see complete prescribing information, including box warning.

The content contained in this website is not intended to be a substitute for professional medical advice related to any topic discussed. Patients are urged to consult with their treating physicians or other professionals. Never disregard professional,medical or legal advice or delay seeking such advice because of something you have read on this website.


PROLEUKIN.com Home  |  What is PROLEUKIN & how does it work?  |  Metastatic Melanoma
Metastatic Kidney Cancer  |  PROLEUKIN Treatment Centers
Additional Resources and Links  |  Stay in Touch  |  Prescribing Information
Important Safety Information  |  INFORMATION FOR HEALTHCARE PROFESSIONALS

Contact Us  |  Site Guide  |  Site Map
Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement.
Copyright ©2008
Novartis Pharmaceuticals Corporation. All rights reserved.